Becker's Healthcare March 6, 2019
Scott Gottlieb, MD, announced his resignation as chief of the FDA on March 5. He plans to leave his post sometime next month.
Dr. Gottlieb has served in his post since May 2017, and has been a staunch advocate for developing new drugs and regulation. His resignation may especially affect biotech and pharmaceutical companies, as well as tech companies looking to move into the healthcare space.
Before appointing Dr. Gottlieb, President Donald Trump considered a variety of candidates for the position, including individuals who sought to dismantle FDA drug oversight and review process — a move that worried many pharma executives and health sector investors, STAT News reports.
“I think Scott was pretty much a...
Today's Sponsors
Today's Sponsor